How Can Allergy Specialists Tailor Treatments for Individuals With Multiple Sensitivities Including Crested Wheatgrass Pollen

Why Crested Wheatgrass Pollen Complicates Multi-Allergen Management

Crested wheatgrass (Agropyron cristatum) produces pollen that shares conserved epitopes with other Poaceae grasses, which means a patient sensitized to crested wheatgrass often tests positive on panels for timothy, orchard, and Bermuda grass as well. The clinical challenge is determining which positive results reflect genuine IgE-mediated sensitization and which are artifacts of protein homology between related species 1.

Polysensitization is common. A 2013 European multicenter study (N=1,263) found that 72.4% of patients with allergic rhinitis were sensitized to two or more unrelated allergen sources 2. In arid and semi-arid regions of North America where crested wheatgrass is planted for erosion control, the grass pollen season overlaps with tree and weed pollen peaks, compounding the diagnostic picture.

Specialists begin by mapping pollen calendars to symptom diaries. If a patient's worst symptoms align with the June-July Poaceae bloom rather than the April birch or September ragweed windows, that temporal correlation narrows the list of drivers. The 2017 AAAAI/ACAAI Practice Parameter on Allergen Immunotherapy states: "Appropriate allergen selection requires correlation of sensitization test results with clinical history and relevant allergen exposures" 3. Without this correlation step, clinicians risk treating sensitizations that are not causing disease.

Component-Resolved Diagnostics: Separating Signal From Noise

Component-resolved diagnostics (CRD) tests IgE against purified or recombinant molecular allergens rather than crude extracts. This distinction matters for grass-polysensitized patients. A patient may show IgE to Phl p 1 (the major timothy Group 1 allergen) and to cross-reactive carbohydrate determinants (CCDs) that inflate results across every grass and many foods 4.

CRD identifies which molecular components drive symptoms. For Poaceae grasses, the clinically significant markers are Group 1 (Phl p 1 / Lol p 1) and Group 5 (Phl p 5) allergens. A 2019 analysis of 742 grass-allergic patients showed that 85% with genuine grass allergy had IgE to Phl p 1, while only 12% of those whose positivity was CCD-mediated showed Phl p 1 IgE above 0.35 kUA/L 5. By testing for these species-specific and group-specific markers, the allergist distinguishes patients who need grass immunotherapy from those who simply have cross-reactive noise.

For a patient sensitized to crested wheatgrass plus dust mites and cat dander, CRD determines the hierarchy. If sIgE to Der p 1 (dust mite) is 45 kUA/L and sIgE to Phl p 1 is 3.2 kUA/L, the dust mite is likely the primary disease driver. That ranking changes the immunotherapy prescription.

Dr. Robert Wood, Director of Pediatric Allergy and Immunology at Johns Hopkins, has noted: "Component testing allows us to move from a shotgun approach to a precision strategy. Treating every positive skin test result with immunotherapy is neither efficient nor evidence-based" 6.

Building a Custom Immunotherapy Protocol

Once the dominant allergens are identified, the allergist selects the immunotherapy route and allergen mix. Two options exist: subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). The choice depends on allergen availability, patient preference, and the complexity of the sensitization profile.

SCIT allows mixing multiple allergens into a single vial set. The 2017 Practice Parameter recommends limiting mixes to allergens that share similar optimal maintenance doses and avoiding combinations where proteolytic enzymes in one extract degrade proteins in another 3. Fungal extracts, for example, contain proteases that can destroy grass pollen proteins if mixed together. A standard approach places grass pollens (including crested wheatgrass extract) in one vial, tree pollens in a second, and perennial allergens (mite, cat, mold) in a third.

SLIT is more limited for polysensitized patients. The FDA has approved single-allergen SLIT tablets for timothy grass (Grastek), ragweed (Ragwitek), and dust mite (Odactra), but no multi-allergen sublingual product is available in the U.S. The GAP trial (N=812) demonstrated that Grastek started 4 months before pollen season and continued for 3 years produced sustained symptom reduction of 27% compared with placebo through at least 2 post-treatment seasons 7. Because crested wheatgrass shares Group 1 allergens with timothy, Grastek may offer partial cross-protection, but data confirming this for Agropyron cristatum specifically are limited.

For a patient with clinically relevant crested wheatgrass, dust mite, and cat allergy, most U.S. allergists select SCIT with a multi-vial protocol. European specialists, who have access to named-patient sublingual drops, may prescribe multi-allergen SLIT formulations, though the 2020 EAACI guideline advises that evidence supporting multi-allergen SLIT remains weaker than for single-allergen approaches 8.

Dose Escalation and Schedule Considerations for Polysensitized Patients

The buildup phase of SCIT typically involves weekly injections over 3 to 6 months, gradually increasing the allergen concentration until the maintenance dose is reached. Polysensitized patients receiving multi-vial protocols face a longer injection visit because each vial is administered separately with 30-minute observation windows between injections.

Cluster and rush protocols compress the buildup into fewer visits. A 2016 randomized trial (N=246) compared conventional weekly buildup with a 6-visit cluster schedule for multi-allergen SCIT and found equivalent efficacy at 12 months with no significant increase in systemic reaction rates (3.1% cluster vs. 2.8% conventional, P=0.74) 9. This schedule can reduce total buildup visits from 20+ to 6, a meaningful advantage for patients juggling multiple commitments.

Seasonal timing also matters. Grass pollen immunotherapy buildup ideally begins in late fall or winter so the patient reaches maintenance dose before the spring Poaceae season. Starting buildup during peak crested wheatgrass pollen exposure (typically June through early August in northern temperate zones) increases the risk of systemic reactions because the patient's immune system is already managing high ambient allergen loads 10.

The maintenance phase continues for 3 to 5 years. The SIT-004 meta-analysis (49 trials, N=6,828) found that SCIT for allergic rhinitis produced a standardized mean difference of −0.65 (95% CI −0.81 to −0.49) in symptom scores versus placebo, with benefits persisting for at least 3 years after discontinuation in patients who completed the full course 11.

Pharmacotherapy Layering During Immunotherapy Buildup

Immunotherapy does not produce immediate symptom relief. During the buildup phase and the first pollen season on treatment, patients need bridging pharmacotherapy.

Second-generation antihistamines form the first line. Cetirizine 10 mg daily or fexofenadine 180 mg daily block H1 receptors without the sedation or anticholinergic effects of first-generation agents 12. For patients whose nasal congestion is the dominant complaint, intranasal corticosteroids (fluticasone propionate 200 mcg/day or mometasone furoate 200 mcg/day) reduce mucosal inflammation and have a stronger effect on obstruction than oral antihistamines alone.

The combination of intranasal corticosteroid plus intranasal azelastine (sold as Dymista) was shown in a 2012 trial (N=610) to reduce total nasal symptom scores by 5.7 points versus 4.4 points for fluticasone alone (P<0.001) 13. This combination is particularly useful during peak crested wheatgrass pollen weeks when immunotherapy has not yet reached full effect.

Montelukast 10 mg daily, a leukotriene receptor antagonist, can be added for patients with concurrent allergic asthma or those who respond poorly to antihistamines. The 2020 FDA boxed warning on montelukast's neuropsychiatric effects means clinicians reserve it for patients whose benefit clearly outweighs the risk 14.

For ocular symptoms driven by grass pollen, olopatadine 0.2% ophthalmic drops once daily or ketotifen 0.025% twice daily provide targeted relief without systemic absorption.

Managing Cross-Reactivity Between Grasses, Foods, and Latex

Polysensitized patients often experience oral allergy syndrome (OAS) triggered by proteins homologous to their pollen allergens. Grass pollen-sensitized individuals may react to wheat, tomato, melon, or peach through profilin (Phl p 12) or polcalcin (Phl p 7) cross-reactivity 15.

The clinical significance varies widely. A 2017 survey of 456 grass-allergic patients found that 24% reported OAS symptoms with at least one food, but only 8% had reactions confirmed by oral food challenge 16. CRD again helps stratify risk. IgE to Pru p 3 (a lipid transfer protein) in a peach-reactive, grass-allergic patient suggests a primary food allergy requiring strict avoidance, while IgE to Phl p 12 (profilin) with negative Pru p 3 suggests mild cross-reactivity that may resolve with grass pollen immunotherapy.

Allergists managing a crested wheatgrass-polysensitized patient should screen for food triggers during history intake and order CRD panels (Phl p 12, Phl p 7, Pru p 3, Tri a 19 for wheat) when food reactions are reported.

Biologics for Patients Who Fail Standard Immunotherapy

A subset of polysensitized patients has such high total IgE or such severe symptoms that standard SCIT produces inadequate relief. Omalizumab (Xolair), a monoclonal anti-IgE antibody, was evaluated as pretreatment before immunotherapy in a 2006 trial (N=221) that showed the combination reduced symptom-severity scores by 48% compared with immunotherapy plus placebo during the first ragweed season 17. This approach has been adopted off-label by some allergists for severely polysensitized patients beginning multi-allergen SCIT.

Dupilumab (Dupixent), an anti-IL-4/IL-13 biologic FDA-approved for moderate-to-severe asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps, reduces type 2 inflammation broadly. The LIBERTY SINUS trials showed a 51% reduction in nasal polyp score at 24 weeks 18. For a polysensitized patient with overlapping allergic rhinitis, asthma, and nasal polyposis, dupilumab addresses the shared inflammatory pathway rather than targeting one allergen at a time.

The 2023 AAAAI guidance document noted: "Biologic add-on therapy should be considered when immunotherapy alone does not achieve adequate disease control in highly polysensitized patients with type 2 comorbidities" 19.

Monitoring Treatment Response and Adjusting the Plan

Allergists track response using validated tools. The Total Nasal Symptom Score (TNSS, 0-12 scale) and the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ, 0-6 scale) provide standardized measures 20. A meaningful clinical improvement on the RQLQ is defined as a decrease of 0.5 points or more.

Objective biomarkers complement symptom scores. Serial measurement of allergen-specific IgG4 (a blocking antibody induced by immunotherapy) and sIgE/total IgE ratios at 12-month intervals can confirm immune modulation is occurring 21. A rising sIgG4 to crested wheatgrass or timothy with stable or declining sIgE suggests the immunotherapy is working.

If a patient shows no improvement after 12 months of maintenance-dose SCIT, the allergist should reassess allergen selection (was a clinically irrelevant allergen included?), extract potency (were degraded extracts used?), and adherence (did the patient miss doses?). Switching from SCIT to SLIT, or adding a biologic, may be warranted.

Pollen exposure varies year to year. An unusually high crested wheatgrass pollen season can temporarily worsen symptoms even in patients responding well to immunotherapy. Allergists use local pollen count data from stations certified by the National Allergy Bureau (NAB) to contextualize symptom flares rather than reflexively changing the treatment plan.

Practical Steps for Patients With Crested Wheatgrass and Co-Sensitivities

Patients can take environmental measures to reduce allergen exposure alongside medical treatment. HEPA filtration (particle removal efficiency of 99.97% at 0.3 microns) in the bedroom reduces indoor grass pollen levels by 40-60% when windows are kept closed during peak hours of 5-10 AM 22. Nasal saline irrigation with isotonic or hypertonic (2%) saline twice daily clears deposited pollen from the nasal mucosa and was shown in a Cochrane review to reduce symptom severity by a mean of 1.3 points on a 10-point scale versus no irrigation 23.

Patients sensitized to crested wheatgrass should avoid mowing or walking through Agropyron fields during pollen season. Showering and changing clothes after outdoor exposure reduces allergen transfer to bedding and indoor surfaces.

The allergist revisits the treatment plan annually, adjusting the immunotherapy mix if new sensitizations emerge or existing ones resolve. Repeat CRD testing at the 2-year mark can reveal whether immunotherapy has shifted the molecular IgE profile, guiding decisions about which allergens to continue and which to drop from the protocol.

Maintenance-dose SCIT every 4 weeks for a minimum of 36 months remains the standard recommendation per the 2017 AAAAI/ACAAI Practice Parameter 3. Patients who discontinue early forfeit the long-term tolerance that distinguishes immunotherapy from symptom-suppressing pharmacotherapy.